Ranbaxy posts Rs 586-cr loss on forex derivatives
News | 09 August 2012
Ranbaxy's ability to launch the Lipitor generic had been doubted, as the US Food and Drug Administration (US FDA) had alleged the company had violated manufacturing practices in the last few years. Products from Ranbaxy's key facilities like Dewas and ...
Click on the link to read the full article at Business Standard
(This link will open in a new window)
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
